Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Steve Fancy who wrote (4122)	4/21/1998 4:56:00 PM
From: Steve Fancy	Read Replies (1) of 6136

IGEN Expands High Throughput Screening Agreement GAITHERSBURG, Md., April 16 /PRNewswire/ -- IGEN International, Inc. (Nasdaq: IGEN - news) announced today that it signed an expanded agreement with Agouron Pharmaceuticals, Inc. (Nasdaq: AGPH -news) to screen drug candidates with a novel application based on IGEN's proprietary ORIGEN technology. Having successfully completed the initial arrangement, the newly added milestone will double the size of the original screening project. In addition, upon completion of the final milestone, Agouron will become the second customer for IGEN's new High Throughput Drug Discovery System, which is in development and based on the electrochemiluminescent module (ECLM(TM)). ECLM is the second generation of IGEN's ORIGEN technology, offering enhanced performance, and miniaturization to one palm-sized component. biz.yahoo.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next